Navigation Links
NIH-Funded Study Is First to Demonstrate Increased Long-Term Survival With Favorable Neurologic Function Among Patients Receiving CPR Using ACSI ResQPump® and ResQPOD® CPR Devices

ROSEVILLE, Minn., Jan. 19, 2011 /PRNewswire/ -- A combination of two devices could save the lives of thousands of cardiac arrest patients each year if implemented nationwide, suggests clinical trial results published in today's online edition of The Lancet. A significantly higher percentage of patients who experienced out-of-hospital cardiac arrest survived after receiving active compression decompression cardiopulmonary resuscitation (ACD CPR) performed with the ResQPump®, and the ResQPOD® impedance threshold device, as compared to those receiving conventional, manual CPR performed with a pair of hands. Both devices are manufactured by Advanced Circulatory Systems, Inc. (ACSI) in Roseville, Minn.

Dr. Tom P. Aufderheide, Professor of Emergency Medicine at the Medical College of Wisconsin in Milwaukee (Wisconsin) was first author and a principal investigator at one of the study sites.

"The goal of resuscitation during cardiac arrest is long-term survival with preservation of brain function," commented Dr. Aufderheide. "This new, effective intervention achieves that goal and is potentially the most significant advancement in the treatment of cardiac arrest since defibrillation."

Ralph J. Frascone, MD, Associate Professor of Emergency Medicine at the University of Minnesota and emergency medical services (EMS) medical director at Regions Hospital in St. Paul (Minnesota) commented further. "Each year, approximately 300,000 Americans experience out-of-hospital cardiac arrest, and the national average for survival to hospital discharge is dismal – only about 5 percent," Dr. Frascone said. "However, in this study, patients who received CPR by rescuers using the device combination had a 53 percent higher survival to hospital discharge rate with favorable neurologic function than those who did not, and, a significant survival benefit was still present one year after the initial cardiac arrest event."

Funded by the National Institutes of Health and sponsored by Advanced Circulatory Systems, Inc., the trial compared survival rates among a control group of 813 cardiac arrest patients receiving standard CPR, to an intervention group of 840 patients receiving ACD CPR, performed using the ResQPump, with an impedance threshold device (ITD), the ResQPOD. All other aspects of patient care, such as airway management, IV fluids, medications, defibrillation, resuscitation length, etc., were similar between the two groups. The randomized, prospective, multi-center trial was performed in seven distinct United States (US) geographic locations, including 46 EMS agencies in urban, suburban, and rural areas serving a total population of 2.3 million. The study showed that CPR using these devices was easy to teach and implement in multiple EMS systems across the country.

In patients with cardiac arrest, time to CPR treatment is critical for survival. In all study patients, EMS CPR was provided within approximately 6 minutes after receiving the 911 call. Importantly, CPR using the study devices was begun within 7 minutes and resulted in not only significantly increased survival, but preserved neurologic function as well. Keith G. Lurie, MD, chief medical officer of Advanced Circulatory Systems, stated, "This was a huge undertaking, involving thousands of EMS providers and hospital personnel over a span of about five years. It is also the first prospective, randomized clinical trial to demonstrate a long-term survival benefit with favorable neurologic benefit using CPR devices."

The ResQPOD® is an impedance threshold device (ITD) that selectively prevents unnecessary respiratory gases from entering the chest during the chest wall recoil phase of CPR. It is attached within the ventilation circuit between the airway device and the ventilation source. By selectively restricting airflow during CPR, the device creates a small but important negative pressure (vacuum) in the chest that has been shown in numerous human and animal clinical trials to increase blood flow back to the patient's heart during CPR.

The ResQPump® is a hand-held, active compression decompression (ACD) CPR device placed in the same position on the sternum as the hands and enabling rescuers to perform similar chest compressions as in conventional CPR. Instead of allowing the chest wall to recoil passively, however, rescuers pull up on the ResQPump's handle with its suction cup. This provides active decompression of the chest, promotes optimal chest wall recoil and creates a negative intrathoracic pressure (vacuum) that helps return blood to the heart. The handle contains a force gauge and metronome that guide compression depth, recoil and rate. The ResQPump is identical to the CardioPump®, an ACD CPR device available for sale outside the US.

About ACSI

Advanced Circulatory Systems, Inc. is a privately held manufacturer of advanced circulatory technology based in Roseville, Minnesota ( Its mission is to restore life and improve the quality of life for patients experiencing cardiac arrest, low blood pressure and head injury by developing new technologies to non-invasively increase circulation throughout the body, improving opportunities for survival and quality of life. The company manufactures and markets the ResQPOD, a version of which is currently available for sale and in use at more than 1,200 hospitals and EMS systems throughout the US, and the CardioPump, which is currently available for sale only outside the US.

SOURCE Advanced Circulatory Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
2. NIH-Funded Study Is First to Demonstrate Increased Long-Term Survival With Favorable Neurologic Function Among Patients Receiving CPR Using ACSI ResQPump™ and ResQPOD® CPR Devices
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
10. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):